Lower-income countries (‎ LICs)‎ in the WHO European Region generally have poorer health
status and more limited resources than higher-income countries. This creates pressing …

Objective Cost-utility analyses are becoming increasingly important in Central and Eastern
Europe. We aimed to develop a Polish utility tariff for EQ-5D-5L health states. Methods Face …

Objectives: Utilization of multisource biological (off-patent originator and its biosimilar)
medicines can improve the efficiency of resource allocation by 1) generating savings while …

Objectives To provide a detailed overview of the recent reforms in pharmaceutical pricing
and reimbursement processes as well as in other important areas of the pharmaceutical …

Introduction Data describing real-world treatment patterns in patients with metastatic
urothelial carcinoma (mUC) in Central-Eastern Europe are scarce, and data from Hungary …

Background Biosimilars constitute a pathway for sustainable financing of healthcare systems
in the era of expensive biologics. However, such a pathway is not free of challenges. Since …

This paper aims to propose a methodological lens to the assessment of technological
innovations in healthcare based on the principles of social, economic, and political …

In recent years, several changes have occurred in the management of chronic
immunological conditions with the emerging use of targeted therapies. This two-phase cross …

Background Efficiency and transparency of pricing and reimbursement (P&R) rules and
procedures as well as their implementation in South-eastern Europe (SEE) lag substantially …

Introduction: Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be
associated with access restrictions in countries with severe economic constraints. This study …